Stay updated on Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T16:45:39.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version (v2.15.0) and includes the addition of 'Non-Small Cell Lung Cancer' and 'Collaborators Exelixis', while significant details about the study's purpose and inclusion/exclusion criteria have been removed.
    Difference
    44%
    Check dated 2025-04-16T11:23:51.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T05:15:18.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T22:23:23.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.9%
    Check dated 2025-02-24T20:17:47.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    0.9%
    Check dated 2025-02-10T09:30:13.000Z thumbnail image

Stay in the know with updates to Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page.